新诊断免疫性血小板减少症的管理:能否改变结局?
本文聚焦成人原发免疫性血小板减少症(ITP),并酌情纳入儿科数据,讨论新诊断患者的一线治疗策略。当前标准一线治疗为糖皮质激素,虽多数患者血小板计数升高,但停药后复发比例高,因此强化一线治疗以改善长期缓解率值得期待。文章旨在概述初治患者的初始策略,并权衡各方案的风险与获益。
要点
- 当前标准一线治疗为糖皮质激素疗程,多数患者血小板计数升高但停药后复发比例高。
- 治疗决策基于止血表现消失、血小板计数升高、预防出血和诱导缓解等因素。
- 本文旨在概述初治ITP患者的初始策略以改善缓解率,并权衡风险与获益。
核心结论
- 当前标准一线糖皮质激素治疗虽使多数患者血小板计数升高,但停药后复发比例高,强化一线治疗以获得更优长期缓解率值得期待。
研究设计与样本
- 本文为聚焦成人原发免疫性血小板减少症(ITP)的论述,酌情纳入儿科数据与实践,旨在概述初治患者的初始治疗策略并权衡风险与获益。
主要发现
- 免疫性血小板减少症由抗体介导的血小板破坏合并血小板生成受损所致,是血小板减少的常见原因。
- 当前标准一线治疗为糖皮质激素疗程,多数患者血小板计数升高,但停药后复发比例高。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Immune thrombocytopenia resulting from antibody-mediated platelet destruction combined with impaired platelet production is a common cause of thrombocytopenia. The decision to treat newly diagnosed patients is based on several factors including ceasing hemorrhagic manifestations, increasing the platelet count, prevention of bleeding, and inducing remission. Current standard first-line therapy is a course of corticosteroids. Although this treatment paradigm increases the platelet count in the majority of patients, a high percentage relapse after discontinuation of corticosteroid therapy. For this reason, intensification of first-line therapy that results in superior long-term remission rates would be desirable. This manuscript focuses primarily on adults with idiopathic thrombocytopenic purpura (ITP), highlighting pediatric data and practice when applicable. The primary aim is to outline upfront strategies for treatment-naive patients with ITP to enhance remission rates, taking into account assessment of the risks and benefits of these approaches.
引用
- Neunert CE. Management of newly diagnosed immune thrombocytopenia: can we change outcomes? Blood Adv. 2017. PMID: 29296878. doi:10.1182/bloodadvances.2017009860
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。